Biohaven Pharmaceutical Holding Company Ltd.
BHVN
BHVN was delisted on the 3rd of October, 2022.
2 hedge funds and large institutions have $21.3M invested in Biohaven Pharmaceutical Holding Company Ltd. in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, reducing their positions, and closing their positions.
100% more funds holding
Funds holding: 1 → 2 (+1)
67% more capital invested
Capital invested by funds: $12.8M → $21.3M (+$8.55M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Birchview Capital
Burlington,
Vermont
|
+$315K |
Top Sellers
BHVN Hedge Fund Activity: Q4 2023 in Review
2 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) for Q4 2023, worth a combined $21.3M — up 67% from $12.8M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new BHVN positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Birchview Capital, opening a new position worth an estimated $315K.
- 2 institutional investors held Biohaven Pharmaceutical Holding Company Ltd. (BHVN) as of Q4 2023, up from 1 in Q3 2023.
- Funds reported $21.3M of Biohaven Pharmaceutical Holding Company Ltd. stock for Q4 2023, up 67% quarter-over-quarter.
- 1 fund opened new Biohaven Pharmaceutical Holding Company Ltd. positions in Q4 2023 and 0 closed out, a net change of +1 holder.
- The largest Biohaven Pharmaceutical Holding Company Ltd. buyer in Q4 2023 was Birchview Capital, an estimated $315K added.
Based on aggregated 13F filings for Q4 2023.